Syndax Pharmaceuticals (SNDX) News Today → Wall Street Legend Warns: 'A Strange Day Is Coming to America' (From Chaikin Analytics) (Ad) Free SNDX Stock Alerts $20.03 -0.25 (-1.23%) (As of 02:14 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 27 at 6:58 AM | marketbeat.comFranklin Resources Inc. Takes Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Franklin Resources Inc. purchased a new position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,352,905 shares of the company's stock, vMay 25 at 1:42 PM | marketbeat.comTrexquant Investment LP Invests $3.10 Million in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Trexquant Investment LP acquired a new stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 143,514 shares of the company's stock, valued at approximately $3May 23, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Teva Pharmaceutical (TEVA), Cencora (COR)May 22, 2024 | marketbeat.comBNP Paribas Financial Markets Purchases 44,906 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)BNP Paribas Financial Markets grew its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 38.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 162,905 shares of the company's stock after buyingMay 22, 2024 | americanbankingnews.comSyndax Pharmaceuticals (NASDAQ:SNDX) Receives "Overweight" Rating from JPMorgan Chase & Co.May 21, 2024 | marketbeat.comSyndax Pharmaceuticals' (SNDX) "Overweight" Rating Reaffirmed at JPMorgan Chase & Co.JPMorgan Chase & Co. reiterated an "overweight" rating and issued a $34.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday.May 19, 2024 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Purchased by Panagora Asset Management Inc.Panagora Asset Management Inc. boosted its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 90.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 174,144 shares ofMay 17, 2024 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Recommendation of "Moderate Buy" by AnalystsShares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eleven analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and ten have issued aMay 16, 2024 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 3.7%Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 3.7%May 15, 2024 | prnewswire.comSyndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of DirectorsMay 13, 2024 | markets.businessinsider.comSyndax Pharmaceuticals (SNDX) Gets a Buy from Stifel NicolausMay 12, 2024 | finance.yahoo.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2024 Earnings Call TranscriptMay 9, 2024 | markets.businessinsider.comBuy Rating for Syndax Pharmaceuticals Amid Strong Financials and Promising Drug CandidateMay 9, 2024 | marketbeat.comCitigroup Lowers Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $30.00Citigroup lowered their target price on shares of Syndax Pharmaceuticals from $32.00 to $30.00 and set a "buy" rating on the stock in a research report on Thursday.May 9, 2024 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Announces Earnings ResultsSyndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.85) EPS for the quarter, topping analysts' consensus estimates of ($0.96) by $0.11. During the same period in the previous year, the firm posted ($0.59) earnings per share.May 9, 2024 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) PT Raised to $40.00Stifel Nicolaus boosted their price target on Syndax Pharmaceuticals from $39.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday.May 9, 2024 | marketbeat.comSyndax Pharmaceuticals' (SNDX) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $41.00 target price on shares of Syndax Pharmaceuticals in a research report on Thursday.May 9, 2024 | finance.yahoo.comSyndax Pharmaceuticals Inc (SNDX) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 9, 2024 | prnewswire.comSyndax Announces Participation at the Bank of America Securities 2024 Health Care ConferenceMay 8, 2024 | msn.comSNDX Stock Earnings: Syndax Pharmaceuticals Beats EPS for Q1 2024May 8, 2024 | finanznachrichten.deSyndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business UpdateMay 8, 2024 | prnewswire.comSyndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business UpdateMay 3, 2024 | prnewswire.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 2, 2024 | marketbeat.comSyndax Pharmaceuticals (SNDX) Scheduled to Post Earnings on WednesdaySyndax Pharmaceuticals (NASDAQ:SNDX) will be releasing earnings before the market opens on Wednesday, May 8, Zacks reports.May 1, 2024 | prnewswire.comSyndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024April 28, 2024 | marketbeat.comJennison Associates LLC Sells 2,296,893 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Jennison Associates LLC reduced its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 97.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 50,780 shares of the company's stock after selling 2,April 26, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Syndax Pharmaceuticals on Strong Drug Pipeline and Strategic PartnershipsApril 26, 2024 | marketbeat.comSyndax Pharmaceuticals' (SNDX) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $41.00 target price on shares of Syndax Pharmaceuticals in a research report on Friday.April 10, 2024 | finance.yahoo.comSyndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology ForumApril 10, 2024 | prnewswire.comSyndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology ForumApril 8, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Syndax Pharmaceuticals (SNDX), Legend Biotech (LEGN)April 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Syndax Pharmaceuticals Amidst Strong Clinical Results and Strategic Growth ProspectsApril 8, 2024 | prnewswire.comSyndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary SessionApril 6, 2024 | finanznachrichten.deSyndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)April 3, 2024 | msn.comCrinetics Pharmaceuticals gains amid pitch at Sohn charity conference (update)March 29, 2024 | msn.com20 European Cities with Highest Weed ConsumptionMarch 29, 2024 | msn.comThis longevity company is letting you check the ‘credit score’ for your health. Here are my surprising results and biological ageMarch 28, 2024 | msn.comSyndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDAMarch 28, 2024 | finance.yahoo.comSyndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid LeukemiaMarch 28, 2024 | seekingalpha.comSyndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite HopeMarch 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Quanterix (QTRX)March 27, 2024 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 4.9%Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 4.9%March 27, 2024 | marketbeat.comTraders Purchase Large Volume of Syndax Pharmaceuticals Put Options (NASDAQ:SNDX)Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock investors purchased 6,251 put options on the stock. This represents an increase of 435% compared to the typical volume of 1,168 put options.March 27, 2024 | marketwatch.comSyndax Says Revumenib NDA Granted FDA Priority ReviewMarch 27, 2024 | markets.businessinsider.comSyndax Announces FDA Priority Review Of NDA For Revumenib For Treatment Of R/R KMT2Ar Acute LeukemiaMarch 27, 2024 | msn.comFDA grants priority review for Syndax leukemia drug, sets action dateMarch 27, 2024 | finance.yahoo.comSyndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute LeukemiaMarch 18, 2024 | finanznachrichten.deSyndax Pharmaceuticals: Syndax Announces Appointment of Steven Closter as Chief Commercial OfficerMarch 18, 2024 | finance.yahoo.comSyndax Announces Appointment of Steven Closter as Chief Commercial OfficerMarch 17, 2024 | marketbeat.comWellington Management Group LLP Has $110.97 Million Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Wellington Management Group LLP lifted its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 2.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,642,446 shares of the compan Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Wall Street Legend Warns: "A Strange Day Is Coming to America" (Ad)Get Your Cash Out of U.S. Banks Immediately Man who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more. SNDX Media Mentions By Week SNDX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNDX News Sentiment▼1.110.92▲Average Medical News Sentiment SNDX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNDX Articles This Week▼93▲SNDX Articles Average Week Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NAMS News ARDX News EVO News KROS News KURA News HRMY News EWTX News GPCR News PTGX News GLPG News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNDX) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressWARNING about the death of the U.S. dollar…Colonial MetalsThe only AI company to buyPorter & CompanyBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsPresident Biden just made a shocking moveStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
